Co-amoxiclav affects cytokine production by human polymorphonuclear cells.
Some antimicrobial agents have been reported to modify the host immune responses both in vivo and in vitro. As we demonstrated previously that co-amoxiclav had beneficial properties which result in enhancement of the microbicidal functions of human poly-morphonuclear cell (PMNs), we investigated the modulatory effect of this combination on cytokine production by human PMNs in vitro. The addition of co-amoxiclav elicited the production by lipopolysaccharide (LPS)-stimulated PMNs of substantial amounts of some cytokines, namely IL-8 and IL-1beta, after the addition of Klebsiella pneumoniae. These cytokine levels were higher than those obtained by PMNs incubated in culture medium only, without co-amoxiclav.
Reato
G
G
Biomedical Science and Human Oncology, University of Turin, Italy.
Cuffini
A M
AM
Tullio
V
V
Palarchio
A I
AI
Bonino
A
A
Foa
R
R
Carlone
N A
NA
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism*; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics; D016209:Interleukin-8 / Q000235:genetics; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008070:Lipopolysaccharides / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism* / Q000382:microbiology; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000235:genetics
D016207:Cytokines; D004791:Enzyme Inhibitors; D007375:Interleukin-1; D016209:Interleukin-8; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D019980:Amoxicillin-Potassium Clavulanate Combination